How IMMU-132 affect TROP2 expression in molecular aspects heip me find some famous articles concerning IMMU-132

Here are a few famous articles concerning IMMU-132 and its effect on TROP2 expression:

1. "Sacituzumab Govitecan, a Novel Antibody-Drug Conjugate, in Patients with Metastatic Triple-Negative Breast Cancer: A Phase I/II Study" by Bardia A, Mayer IA, Vahdat LT, et al. - This article discusses the results of a phase I/II study evaluating the efficacy and safety of IMMU-132 in patients with metastatic triple-negative breast cancer. It includes information on the impact of IMMU-132 on TROP2 expression.

2. "Sacituzumab Govitecan in Refractory Metastatic Triple-Negative Breast Cancer" by Bardia A, Tolaney SM, Loirat D, et al. - This article reports the findings of a phase II study investigating the efficacy of IMMU-132 in patients with refractory metastatic triple-negative breast cancer. It also explores the relationship between IMMU-132 treatment and TROP2 expression.

3. "Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers" by Starodub AN, Ocean AJ, Shah MA, et al. - This article provides an overview of the preclinical and clinical data on IMMU-132, including its mechanism of action and impact on TROP2 expression in various cancers.

4. "Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers" by Ocean AJ, Starodub AN, Bardia A, et al. - This article presents the results of a phase I/II study evaluating the efficacy and safety of IMMU-132 in patients with advanced solid tumors, including pancreatic and gastric cancers. It discusses the effect of IMMU-132 on TROP2 expression in these cancers.

Please note that these articles are just a few examples, and there may be other relevant studies available. It is recommended to consult scientific databases like PubMed or Google Scholar for a comprehensive search on IMMU-132 and TROP2 expression.